Compare CDT & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDT | SER |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | 6 | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 19.4M |
| IPO Year | N/A | N/A |
| Metric | CDT | SER |
|---|---|---|
| Price | $2.46 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 83.2K | ★ 219.1K |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $1.22 |
| 52 Week High | $11.00 | $7.92 |
| Indicator | CDT | SER |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 43.48 |
| Support Level | $0.66 | $1.77 |
| Resistance Level | $2.48 | $1.86 |
| Average True Range (ATR) | 0.69 | 0.14 |
| MACD | -0.34 | -0.03 |
| Stochastic Oscillator | 2.08 | 12.20 |
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.